Congested OTC Monograph Process Can Leave Manufacturers Confused
This article was originally published in The Tan Sheet
Executive Summary
The disparity between FDA's OTC monographs and up-to-date communications from the agency can create confusion for manufacturers, Office of New Drugs Director John Jenkins acknowledges
You may also be interested in...
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice
Sea Changes In Regulation And The Market: Top Stories Of 2008
When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice